BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,876,823 | -18.3% | 86,335 | -2.0% | 2.88% | -9.9% |
| Q2 2023 | $7,194,460 | +8.4% | 88,135 | -1.5% | 3.20% | +0.8% |
| Q1 2023 | $6,635,183 | -5.9% | 89,435 | +5.1% | 3.17% | -11.0% |
| Q4 2022 | $7,049,773 | +12.5% | 85,060 | +285.7% | 3.56% | +5.5% |
| Q3 2022 | $6,264,000 | -19.4% | 22,055 | -1.6% | 3.38% | -13.6% |
| Q2 2022 | $7,767,000 | -19.7% | 22,405 | +0.4% | 3.91% | +9.3% |
| Q1 2022 | $9,668,000 | -16.2% | 22,325 | +0.1% | 3.57% | -4.1% |
| Q4 2021 | $11,536,000 | +4.0% | 22,300 | -2.6% | 3.73% | -2.1% |
| Q3 2021 | $11,097,000 | -5.9% | 22,900 | -12.6% | 3.81% | -8.5% |
| Q2 2021 | $11,797,000 | +19.3% | 26,200 | +1.2% | 4.16% | +10.1% |
| Q1 2021 | $9,892,000 | +13.9% | 25,900 | -5.3% | 3.78% | +9.5% |
| Q4 2020 | $8,685,000 | +23.4% | 27,350 | -3.7% | 3.45% | +7.2% |
| Q3 2020 | $7,040,000 | -5.9% | 28,415 | +0.3% | 3.22% | -13.1% |
| Q2 2020 | $7,484,000 | +36.6% | 28,340 | -1.9% | 3.70% | +17.9% |
| Q1 2020 | $5,479,000 | -24.0% | 28,890 | -12.0% | 3.14% | -1.8% |
| Q4 2019 | $7,205,000 | +8.8% | 32,822 | -3.0% | 3.20% | +1.5% |
| Q3 2019 | $6,623,000 | -6.7% | 33,847 | -0.6% | 3.16% | -2.7% |
| Q2 2019 | $7,098,000 | +4.1% | 34,047 | -0.9% | 3.24% | -3.4% |
| Q1 2019 | $6,821,000 | +36.0% | 34,350 | -0.9% | 3.36% | +7.4% |
| Q4 2018 | $5,015,000 | -30.3% | 34,650 | -1.7% | 3.12% | -5.5% |
| Q3 2018 | $7,195,000 | +30.5% | 35,250 | -5.4% | 3.30% | +13.7% |
| Q2 2018 | $5,515,000 | -2.2% | 37,275 | -0.1% | 2.91% | -1.8% |
| Q1 2018 | $5,638,000 | +9.0% | 37,325 | -6.5% | 2.96% | +11.4% |
| Q4 2017 | $5,173,000 | -0.3% | 39,925 | -7.0% | 2.66% | -0.4% |
| Q3 2017 | $5,189,000 | +2.9% | 42,925 | 0.0% | 2.67% | -4.3% |
| Q2 2017 | $5,044,000 | +15.6% | 42,925 | 0.0% | 2.79% | +6.2% |
| Q1 2017 | $4,364,000 | -1.1% | 42,925 | 0.0% | 2.62% | -8.7% |
| Q4 2016 | $4,414,000 | -10.6% | 42,925 | -4.8% | 2.87% | -6.5% |
| Q3 2016 | $4,939,000 | -3.0% | 45,100 | -0.1% | 3.07% | -7.4% |
| Q2 2016 | $5,092,000 | +18.0% | 45,150 | -1.1% | 3.32% | +19.3% |
| Q1 2016 | $4,315,000 | – | 45,650 | – | 2.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |